Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors

A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.

Authors

Institutions

Publication Details

Journal
Bone Marrow Transplantation
Published
2025-04-18
DOI
https://doi.org/10.1038/s41409-025-02600-7
Citations
3
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
5.31
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors

David Gómez‐Almaguer, Calixto Hernández Cruz, Guillermina Remaggi, Carmem Bonfim et al.
3 citations
Bone Marrow Transplantation
Hematopoietic Stem Cell Transplantation
5.31
article

Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors

David Gómez‐Almaguer, Calixto Hernández Cruz, Guillermina Remaggi, Carmem Bonfim, Félix Gaytán Morales, María Liz Benítez, Helen Baldomero, Guillermo J. Ruíz‐Argüelles, Ana Lisa Basquiera, Andrés Gómez‐De León, Damiano Rondelli, Cinthya Correa, Marcos Hernández, Anderson João Simione, Dietger Niederwieser, Francisco M. Barriga, Daniel Neumann, Bárbara Puga, Gustavo Bettarello, Ariel Amaru, Adriana Seber, Matías Sánchez, Alfredo Wong-Chang, Gregorio Jaimovich, Nicolás Mendoza, Sebastián Galeano, Mariano Berro, Carolina Pagés, Amado Karduss, Juan Manuel Herrera, Fernando Barroso, Cristóbal Frutos, Julia Palma
article en
3 citations

Abstract

A total of 6767 first hematopoietic cell transplants (HCT), 4121 autologous (61%) and 2646 allogeneic (39%), were reported by 166 teams from 12 Latin American countries that answered the 2022 LABMT/WBMT activity survey. The transplant rate (TR) for Latin America in 2022 was 103 HCT/10 million inhabitants with a wide variation between the different countries. The main indication for allogeneic (allo)-HCT was acute lymphoblastic leukaemia (41%) for the pediatric population and acute myeloid leukemia (32%) for adults. The main indication for autologous (auto)-HCT was neuroblastoma (33%) in children and plasma cell disorders (57%) in adults. In alloHCT, the most used hematopoietic cell source was the bone marrow (54%) in pediatric while peripheral blood stem cells (PBSC) (87%) was in adults. PBSC was the source of choice for autoHCT in both ages. The main trends observed in the period 2019-2022 was a decrease in the number of procedures in 2020 in association with the start of the COVID-19 pandemic, resuming growth in the following years. AlloHCT had a greater growth compared to autoHCT, and it was mainly driven by the utilization of haploidentical related donors, which became the main source from 2020 onwards.

Bone Marrow TransplantationVol. 60(7)
Hospital Británico (UY), Universidad Autónoma de Nuevo León (MX), Fundación Chile (CL), Hermanos Ameijeiras Hospital (CU), Hospital Israelita Albert Einstein (BR), Organización Nacional de Trasplantes (ES), University Hospital of Basel (CH), University of Illinois Chicago (US), Instituto de Cancerología Las Américas (CO), Hospital Samaritano de São Paulo (BR), Hospital Infantil de México Federico Gómez (MX), Hospital del Salvador (CL), Hospital Universitario Austral (AR), Hospital Universitário Walter Cantídio (BR), Hospital Erasto Gaertner (BR), Hospital Amaral Carvalho (BR), Fundación para la Investigación, Docencia y Prevención del Cáncer (AR), Hospital Universitario Dr José Eleuterio Gonzalez (MX), Hospital Universitário de Brasília (BR), Hospital Privado (AR), Hospital del Niño (PA), Fundación IRAUy (UY), Clínica Ruiz (MX), Hospital São Paulo (BR), Academia Nacional de Ciencias de Bolivia (BO), IPS Central (PY), Leipzig University (DE)
Good health and well-being
Openalex Percentile: Top 5%
Hematopoietic Stem Cell Transplantation
5.31
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.